B+
Bull case
30%
Probability
Target price
$74.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
PCVX
VaxcyteCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The company source confirms a funded sequence of clinical milestones: adult VAX-31 studies are fully enrolled, OPUS-1 data are expected in Q4 2026, additional Phase 3 readouts are expected in 1H 2027, and liquidity was approximately $2.5 billion. The Q2 EPS result also modestly exceeded external consensus by $0.09, although revenue comparison was unavailable.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +6.4.
What can break
Clinical-stage cash burn and future financing could create dilution despite the current liquidity position.
Momentum
92
Value
41
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $61.00 · Bull $74.00 · Bear $39.00Analysis 2026-08-17; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $117.30
Why
Momentum92 · Δ7d +2.2
Value41 · Δ7d -0.1
Sentiment55 · Δ7d +6.4
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +6.4.
Contradictions & invalidation
- • Clinical-stage cash burn and future financing could create dilution despite the current liquidity position.
- • Commercial positioning faces established PCV20 and PCV21 competitors.
- • The investment case remains dependent on binary clinical, manufacturing, regulatory, and competitive execution against established PCV20 and PCV21 products.
Catalyst clock
2026-08-05
Q2 EPS modestly beat external consensus
Lead driver: Sentiment · See AI snapshot
Momentum
92
8% active weight
Current posture
7d trendFlat
Δ7d
+2.2
Δ21d
+34.7
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
55
45% active weight
Current posture
7d trendImproving
Δ7d
+6.4
Δ21d
-17.7
Why this grade
Composite grade C. Momentum 92.0 / Value 40.6 / Sentiment 55.5
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-17. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$61.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$39.00
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$9.51B
Beta
1.33
Shares Out
157.39M
P/E (TTM) · Derived
-10.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-9.05
Rev YoY
-
EPS YoY
+60.7%
Gross Margin
-
Op Margin
-
Net Debt
-$1.44B
Current Ratio
5.72
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data